|
|
Latest Cervical Cancer News
Study Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (8/9/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.
HPV Vaccine Protects Against Genital Warts and Precancerous Growths (7/30/2010)
Results from a recent international study indicate that the vaccine Gardasil® (quadrivalent human papillomavirus [types 6, 11, 16, 18] recombinant vaccine) protects against genital warts and low-grade precancerous changes to the cervix, vulva, and vagina. These findings were published in the journal BMJ.
Many Physicians Fail to Adhere to New Cervical Cancer Screening Guidelines (7/12/2010)
Apparently, old habits die hard: less than one-third of physicians report compliance with the updated guidelines for cervical cancer screening that suggest longer intervals between screening for women with normal test results.
More Than Half of Young Adults in New Relationships Infected with HPV (4/26/2010)
More than half of young adults in a new sexual relationship are infected with human papillomavirus (HPV), and of those 44% were infected with an HPV type that causes cancer, according to the results of a groundbreaking study called the HITCH Cohort Study (HPV Infection and Transmission in Couples through Heterosexual activity).
Cervical Vaccine Provides Little Benefit for Older Women (3/4/2010)
Women over the age of 40 are not likely to benefit from a vaccine designed to prevent human papillomavirus (HPV), according to the results of a study published in the Journal of the National Cancer Institute.1 HPV has been shown to cause cervical cancer.
Cervical Cancer News By Topic
Cervical Cancer - Screening/PreventionHPV Vaccine Protects Against Genital Warts and Precancerous Growths (7/30/2010)
Results from a recent international study indicate that the vaccine Gardasil® (quadrivalent human papillomavirus [types 6, 11, 16, 18] recombinant vaccine) protects against genital warts and low-grade precancerous changes to the cervix, vulva, and vagina. These findings were published in the journal BMJ.
Many Physicians Fail to Adhere to New Cervical Cancer Screening Guidelines (7/12/2010)
Apparently, old habits die hard: less than one-third of physicians report compliance with the updated guidelines for cervical cancer screening that suggest longer intervals between screening for women with normal test results.
More Than Half of Young Adults in New Relationships Infected with HPV (4/26/2010)
More than half of young adults in a new sexual relationship are infected with human papillomavirus (HPV), and of those 44% were infected with an HPV type that causes cancer, according to the results of a groundbreaking study called the HITCH Cohort Study (HPV Infection and Transmission in Couples through Heterosexual activity).
Cervical Vaccine Provides Little Benefit for Older Women (3/4/2010)
Women over the age of 40 are not likely to benefit from a vaccine designed to prevent human papillomavirus (HPV), according to the results of a study published in the Journal of the National Cancer Institute.1 HPV has been shown to cause cervical cancer.
Cervarix® Protection Extends Beyond Six Years (2/12/2010)
Cervarix®—a vaccine that reduces the risk of cervical cancer by protecting against two high-risk types of human papillomavirus (HPV)—remains effective for more than six years. These results were published in the Lancet.
Cervical Cancer - Stage IJanuary Is National Cervical Cancer Awareness Month (1/4/2010)
As the month of January brings cervical cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated cervical cancer information throughout the year.
Sentinel Node Biopsy Is a Minimally-invasive, Effective Method for Determining Spread of Cervical Cancer (6/9/2009)
The majority of women with cervical cancer can safely undergo sentinel node biopsy instead of full pelvic lymph node dissection to determine the spread of their disease, thereby avoiding the complications associated with the more invasive procedure, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.
Cancer Consultants Offers Free Subscriptions to Women&Cancer Magazine (12/1/2008)
Women&Cancer is the premier women’s health and wellness magazine. By covering all health and wellness issues with an emphasis on cancer prevention, early detection, management, and survivorship, Women&Cancer empowers women with regard to their own health and recognizes the unique role of women in the overall health of their family and friends.
Robotically-assisted Hysterectomy Appears Effective for Cervical Cancer (11/18/2008)
Robotically-assisted hysterectomy (RAH) in patients with early-stage cervical cancer is at least as effective as traditional open radical hysterectomy (ORH) and produces fewer complications, according to the results of a study published in the October 2008 issue of the American Journal of Obstetrics and Gynecology.
Updates in the Management of Gynecologic Cancers (5/27/2008)
A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists
Cervical Cancer - Stages II-IVAStudy Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (8/9/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.
January Is National Cervical Cancer Awareness Month (1/4/2010)
As the month of January brings cervical cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated cervical cancer information throughout the year.
Gemzar® Added to Chemoradiation Improves Survival in Locally Advanced Cervical Cancer (6/8/2009)
The combination of Gemzar® (gemcitabine), Platinol® (cisplatin), and concurrent radiation significantly improves survival over single-agent Platinol and radiation in women with Stage IIB-IVA cervical cancer, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.
Cancer Consultants Offers Free Subscriptions to Women&Cancer Magazine (12/1/2008)
Women&Cancer is the premier women’s health and wellness magazine. By covering all health and wellness issues with an emphasis on cancer prevention, early detection, management, and survivorship, Women&Cancer empowers women with regard to their own health and recognizes the unique role of women in the overall health of their family and friends.
Robotically-assisted Hysterectomy Appears Effective for Cervical Cancer (11/18/2008)
Robotically-assisted hysterectomy (RAH) in patients with early-stage cervical cancer is at least as effective as traditional open radical hysterectomy (ORH) and produces fewer complications, according to the results of a study published in the October 2008 issue of the American Journal of Obstetrics and Gynecology.
Cervical Cancer - Metastatic/Stage IVBJanuary Is National Cervical Cancer Awareness Month (1/4/2010)
As the month of January brings cervical cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated cervical cancer information throughout the year.
Cancer Consultants Offers Free Subscriptions to Women&Cancer Magazine (12/1/2008)
Women&Cancer is the premier women’s health and wellness magazine. By covering all health and wellness issues with an emphasis on cancer prevention, early detection, management, and survivorship, Women&Cancer empowers women with regard to their own health and recognizes the unique role of women in the overall health of their family and friends.
Updates in the Management of Gynecologic Cancers (5/27/2008)
A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists
Cervical Cancer Survivors Face Risk of Second Cancers (4/27/2007)
According to the results of a study presented at the 2007 annual meeting of the American Association for Cancer Research (AACR), the risk of a second cancer among women with a history of cervical cancer is higher than the cancer risk in the general population.
Hycamtin® Approved for Advanced Cervical Cancer (6/19/2006)
According to a press release from GlaxoSmithKline, Hycamtin® (topotecan) was recently approved by the U.S. Food and Drug Administration (FDA) for a new use—the treatment of stage IVB, recurrent, or persistent cervical cancer, when given in combination with Platinol® (cisplatin).
Cervical Cancer - RecurrentJanuary Is National Cervical Cancer Awareness Month (1/4/2010)
As the month of January brings cervical cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated cervical cancer information throughout the year.
Avastin® Shows Promise in Treatment of Cervical Cancer (3/2/2009)
According to the results of a Phase II clinical trial, the targeted therapy Avastin® (bevacizumab) warrants further investigation in the treatment of persistent or recurrent squamous cell carcinoma of the cervix. These results were published in the Journal of Clinical Oncology.
Cancer Consultants Offers Free Subscriptions to Women&Cancer Magazine (12/1/2008)
Women&Cancer is the premier women’s health and wellness magazine. By covering all health and wellness issues with an emphasis on cancer prevention, early detection, management, and survivorship, Women&Cancer empowers women with regard to their own health and recognizes the unique role of women in the overall health of their family and friends.
Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers (3/17/2008)
The administration of the blood cell growth factor Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective as and more convenient than second-day administration. These results were recently reported at the 2008 annual Society of Gynecologic Oncologists meeting.
Cervical Cancer Survivors Face Long-term Risk of Second Cancers (11/1/2007)
According to the results of a study published in the Journal of the National Cancer Institute, cervical cancer survivors have an increased risk of later developing other types of cancer, particularly if their cervical cancer was treated with radiation therapy. This increased risk persists for more than 40 years after the cervical cancer diagnosis.
|
|
